11 July 2018 - - Hsinchu, Taiwan-based biopharmaceutical company JHL Biotech, Inc. has received approval by the Center for Drug Evaluation, State Drug Administration of China, of JHL's phase I and phase III clinical trial application for a proposed rituximab biosimilar, JHL1101, to treat non-Hodgkin lymphoma, the company said.
JHL1101 is currently undergoing clinical trials in the EU and is being developed for many indications including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, follicular lymphoma, diffuse large B cell lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiites, and microscopic polyangiites.
JHL is an innovator in biopharmaceuticals that utilizes breakthrough engineering and process technologies to provide high quality, affordable biosimilar medicines.
Founded in 2012 by a group of industry veterans with deep experience in biologics development and operations, the mission of JHL Biotech is to provide the world with affordable medicines of exceptional quality.
With a manufacturing facility in Wuhan, China, the company is focused on research and development of new protein-based therapies and proprietary biosimilars.